MYOMO, INC. (MYO)

The company is a wearable medical robotics business focused on functional improvement for people with neuromuscular disorders and upper limb paralysis. It develops and markets the MyoPro product line, a myoelectric-controlled upper limb brace (orthosis) that supports a weak or paralyzed arm and helps improve activities of daily living at home and in the community. Its patented, non-invasive electromyography (EMG) control technology senses the user's own weak muscle signals and activates small motors to move the limb. The device only moves while the user is actively trying to move. The company's stated strategy is to become the market leader in myoelectric limb orthotics and to build products, software applications and value-added services on this technology platform.

The company operates as one business segment. The MyoPro is a custom-fabricated elbow-wrist-hand orthosis made of lightweight metal, with signal processing software, sensors, small motors, a lightweight battery and 3D printed components unique to each patient. It is listed with the FDA as a Class II (510(k)-exempt) biofeedback device and is billed under two brace codes: L8701 (Motion W, a multi-articulated non-powered wrist) and L8702 (Motion G, with a powered grasp). Most braces are billed as L8702. The company expects to introduce the MyoPro3, an improvement on the current MyoPro2x, and a pediatric device called MyoPal at a future date. It holds 35 patents in the U.S. and other countries, expiring from 2027 through 2042, has 14 pending applications, and also relies on trade secrets in control software and mechanical design.

The devices are intended for adolescents and adults with conditions such as stroke, brachial plexus injury, traumatic brain injury, spinal cord injury, cerebral palsy and other neurological disorders, and in a few cases progressive conditions such as multiple sclerosis. The company's addressable market centers on U.S. stroke survivors. It cites about 6.3 million stroke survivors, of whom roughly 3.8 million have moderate to severe upper extremity impairment, and estimates that 10% to 20% may be medically qualified candidates whose insurance may reimburse the device. Medicare Part B beneficiaries are now included. A physician's prescription is required for reimbursement. Most sales go directly to patients, with the company billing insurers itself (direct billing). It also sells through orthotics and prosthetics (O&P) providers at wholesale prices, which it expects to contribute more revenue in the future, through the Veterans Administration, and to certain accounts outside the U.S. It works with rehabilitation facilities including Cleveland Clinic, Spaulding Rehabilitation Hospital, Loma Linda University Medical Center, Kennedy Krieger Institute, the University of Utah and numerous VA Medical Centers. CMS reimbursement rates were updated effective January 1, 2026, to about $34,970 for L8701 and $68,800 for L8702.

Patient arm measurements are captured in person or remotely with the company's shape capture kit. The orthotic parts are 3D printed by a subcontractor, and the company completes brace fabrication in-house, typically in under two weeks. The brace is then delivered and fitted by the company, an O&P practice or VA staff. It is calibrated to the user's muscle signals with proprietary software, and the patient receives initial training. The company believes the MyoPro is the only commercially available device in the U.S. that helps partially paralyzed people regain arm and hand movement using their own muscle signals. Other interventions mentioned include occupational therapy, electrical stimulation and static braces. The company is headquartered in Burlington, Massachusetts.